Table 2.
Neuropathologic characteristics of the three study groups
| No. or median (% or interquartile range) | ||||
|---|---|---|---|---|
| Characteristic | gFTLD-TDP (n=15) | AD-TDP (n=10) | Pure-TDP (n=10) | p-value |
| Time to autopsy, hours | 3 (3 – 5) | 18 (4 – 19) | 8.5 (3 – 14) | 0.13 |
| Brain weight, grams | 920 (740 – 1040) | 980 (818 – 1095) | 970 (900 – 1180) | 0.37 |
| Tau | ||||
| Median Braak NFT stage | 2.5 (1 – 3) | 5.5 (4 –6) | 1 (1 – 2) | <0.0001a,c |
| Braak 0 | 2 (13%) | 0 (0%) | 1 (10%) | |
| Braak I | 2 (13%) | 0 (0%) | 5 (50%) | |
| Braak II | 3 (20%) | 0 (0%) | 3 (30%) | |
| Braak III | 5 (33%) | 0 (0%) | 1 (10%) | |
| Braak IV | 1 (7%) | 2 (20%) | 0 (0%) | |
| Braak V | 2 (13%) | 3 (30%) | 0 (0%) | |
| Braak VI | 0 (0%) | 5 (50%) | 0 (0%) | |
| Amyloid-ß | ||||
| Median CERAD | 0 (0 – 0) | 3 (1 – 3) | 0 (0 – 0) | <0.0001a,c |
| Median Thal phase | 1 (0 – 2) | 5 (4 – 5) | 1 (0 – 1) | <0.0001a,c |
| 0 (no amyloid-β) | 5 (33%) | 0 (0%) | 4 (40%) | |
| 1 (neocortical) | 6 (40%) | 0 (0%) | 4 (40%) | |
| 2 (allocortex) | 2 (13%) | 0 (0%) | 2 (20%) | |
| 3 (thalamus, striatum) | 1 (7%) | 0 (0%) | 0 (0%) | |
| 4 (brainstem) | 1 (7%) | 4 (40%) | 0 (0%) | |
| 5 (cerebellum) | 0 (0%) | 6 (60%) | 0 (0%) | |
| TDP-43 type | ||||
| Type A/alpha | 13 (87%) | 10 (100%) | 9 (90%) | 0.77 |
| Type B | 2 (13%) | 0 (0%) | 1 (10%) | |
| Alzheimer’s disease neuropathologic changes | ||||
| High/intermediate likelihood | 3 (20%) | 10 (100%) | 0 (0%) | |
| Low likelihood/none | 12 (80%) | 0 (0%) | 10 (100%) | <0.0001a,c |
| Hippocampal sclerosis | 10 (67%) | 7 (70%) | 8 (80%) | 0.89 |
| moderate/severe | 9 (60%) | 7 (70%) | 8 (80%) | 0.60 |
| Lewy body disease | 0 (0%) | 4 (40%) | 1 (10%) | 0.015 a |
| Incidental | 0 (0%) | 0 (0%) | 1 (10%) | |
| Brainstem-predominant | 0 (0%) | 1 (10%) | 0 (0%) | |
| Amygdala-predominant | 0 (0%) | 0 (0%) | 0 (0%) | |
| Transitional/limbic | 0 (0%) | 2 (20%) | 0 (0%) | |
| Diffuse/neocortical | 0 (0%) | 1 (10%) | 0 (0%) | |
| Cerebrovascular disease | ||||
| Vascular score (0 – 4) | 1 (0 – 2) | 2 (1 – 3) | 1.5 (1 – 4) | 0.20 |
| 0 (no lesions) | 7 (47%) | 0 (0%) | 2 (20%) | |
| 1 (mild CAA/arteriolosclerosis) | 1 (7%) | 4 (40%) | 3 (30%) | |
| 2 (≥moderate CAA/arteriolosclerosis) | 4 (27%) | 2 (20%) | 1 (10%) | 0.12 |
| 3 (micro-infarcts, no large infarcts) | 2 (13%) | 2 (20%) | 1 (10%) | |
| 4 (lacunar/large infarcts) | 1 (7%) | 2 (20%) | 3 (30%) | |
| Other pathologies | ||||
| Argyrophilic grains disease | 2 (13%) | 0 (0%) | 0 (0%) | 0.50 |
Data are represented as median (interquartile range) for continuous variables or number (per cent) for categorical variables. P-values are from Kruskal-Wallis test for continuous variables or Fisher’s exact test for categorical variables
a
significant difference between gFTLD-TDP and AD-TDP, p<0.05
b
significant difference between gFTLD-TDP and pure-TDP, p<0.05
c
significant difference between AD-TDP and pure-TDP, p<0.05